Status:
COMPLETED
Determination of Absorption and Elimination of Lamotrigine-XR
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Epilepsy
Seizures
Eligibility:
All Genders
65+ years
Phase:
PHASE1
PHASE2
Brief Summary
People over 65 years of ag break down (metabolize) drugs differently than younger adults. It is not known why this happens or how elderly people absorb or break down these drug differently. These diff...
Detailed Description
If you agree to be in this study you will be admitted in to the General Clinical Research Center (GCRC) for approximately 24 hours on two different days (Part 1 and Part2). We will need you take a por...
Eligibility Criteria
Inclusion
- Clinical Diagnosis of Epilepsy or Bipolar Depression
- able to have a venus catheter implanted for blood withdrawal and for intravenous infusion
- equal to or over the age of 65
Exclusion
- not on any medication that will interact with lamotrigine e.g. carbamazepine, phenytoin, phenobarbital, valproic acid, St. John's wort, rifampin, tamoxifen
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00789113
Start Date
November 1 2008
End Date
January 1 2011
Last Update
January 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55404